BR112022012594A2 - Dosagem de gama-hidroxibutirato (ghb) - Google Patents

Dosagem de gama-hidroxibutirato (ghb)

Info

Publication number
BR112022012594A2
BR112022012594A2 BR112022012594A BR112022012594A BR112022012594A2 BR 112022012594 A2 BR112022012594 A2 BR 112022012594A2 BR 112022012594 A BR112022012594 A BR 112022012594A BR 112022012594 A BR112022012594 A BR 112022012594A BR 112022012594 A2 BR112022012594 A2 BR 112022012594A2
Authority
BR
Brazil
Prior art keywords
ghb
hydroxybutyrate
gamma
dosage
narcolepsy
Prior art date
Application number
BR112022012594A
Other languages
English (en)
Inventor
Skobieranda Franck
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of BR112022012594A2 publication Critical patent/BR112022012594A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

A presente invenção refere-se a métodos de administração de formulações de GHB para o tratamento de narcolepsia e outras condições.
BR112022012594A 2019-12-24 2020-12-22 Dosagem de gama-hidroxibutirato (ghb) BR112022012594A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US202063052676P 2020-07-16 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
BR112022012594A2 true BR112022012594A2 (pt) 2022-09-06

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012594A BR112022012594A2 (pt) 2019-12-24 2020-12-22 Dosagem de gama-hidroxibutirato (ghb)

Country Status (14)

Country Link
US (2) US20210186907A1 (pt)
EP (1) EP4081204A1 (pt)
JP (1) JP2023508975A (pt)
KR (1) KR20220119429A (pt)
CN (1) CN115209885A (pt)
AU (1) AU2020414694A1 (pt)
BR (1) BR112022012594A2 (pt)
CA (1) CA3162974A1 (pt)
CL (1) CL2022001743A1 (pt)
CO (1) CO2022010330A2 (pt)
IL (1) IL294176A (pt)
MX (1) MX2022007968A (pt)
TW (1) TW202135790A (pt)
WO (1) WO2021133778A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69907508T2 (de) 1998-12-23 2003-11-20 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
EP1325014B1 (en) 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyrate compositions containing carbohydrate carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
EP4081204A1 (en) 2022-11-02
CN115209885A (zh) 2022-10-18
MX2022007968A (es) 2022-09-02
US20210361601A1 (en) 2021-11-25
US20210186907A1 (en) 2021-06-24
TW202135790A (zh) 2021-10-01
IL294176A (en) 2022-08-01
WO2021133778A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
KR20220119429A (ko) 2022-08-29
CO2022010330A2 (es) 2022-10-21
CA3162974A1 (en) 2021-07-01
JP2023508975A (ja) 2023-03-06
CL2022001743A1 (es) 2023-02-10

Similar Documents

Publication Publication Date Title
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
CO2021005987A2 (es) Compuestos de anillo fusionado
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
UY37391A (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
BR112022008294A2 (pt) Composições de profármaco e métodos de tratamento
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017008312A2 (pt) novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms)
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
CO2022000270A2 (es) Inhibidores de enzimas
BR112017016378A2 (pt) composições da pró-droga de fumarato de monometila
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов